AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

In this interview, rare disease expert Oxana Iliach discusses challenges with rare disease drug development and how they can ...

"Chemical endocytic medicinal chemistry has the potential to impact every aspect of endocytic drugs from drug discovery and development to clinical practice," said Li. In this novel process ...

Center at UCSF is pioneering the development of potent drug candidates aimed at preventing future coronavirus pandemics.

To address these challenges, an AI model was generated to segment spleens from diverse 3D ultrasound images taken ... portfolio of oncology drug discovery and development services, we are ...

AI is revolutionising the pharmaceutical industry, as highlighted at Reuters Pharma 2025, with transformative applications ...

FibroMAP combines the power of high-resolution, single-fiber, and spatially resolved datasets generated by PharmaNest's ...

BigHat will retain full global rights and development control over the ADC. The deal represents a continued push by Lilly to ...

Executing GATC Health's Strategic Vision Dr. Gupta's forward-thinking policies while at the White House delivered a ...

GenAI offers a realistic path forward in tackling previously undruggable targets, with the potential to reshape the entire therapeutic landscape and the whole drug discovery pipeline.

Intellomx announces its' new Pilot platform, delivering rapid identification of novel drugs arising from its therapeutic ...